سعر افيروثيازيد 5/40/25 مجم 30 قرص 2024

Fixed-dose triple antihypertensive combination (Averothiazide, Averroes Pharma, Egypt): each film-coated tablet contains amlodipine 5 mg, olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg; 30 tablets (3 strips x 10).

• Treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure (lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events).Population: AdultsDailyMed (U.S. National Library of Medicine)

• In the controlled trial of the 40/10/25 mg combination, adverse reactions in at least 2% included peripheral oedema (7.7%), headache (6.4%), fatigue (4.2%), nasopharyngitis (3.5%), muscle spasms (3.1%), nausea (3.0%), upper respiratory tract infection (2.8%), diarrhoea (2.6%), urinary tract infection (2.4%) and joint swelling (2.1%); dizziness was among the most frequent and the most common reason for discontinuation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Anuria (hydrochlorothiazide component).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to any component or to other sulfonamide-derived drugs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Co-administration with aliskiren in patients with diabetes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Symptomatic hypotension may occur after initiation in volume- and/or salt-depleted patients; start under close medical supervision. Symptomatic hypotension with amlodipine is possible, particularly in severe aortic stenosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increased angina and/or myocardial infarction may occur on starting or increasing a calcium channel blocker, particularly in severe obstructive coronary artery disease.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Impaired renal function (oliguria, progressive azotaemia, rarely acute renal failure) may occur in patients whose renal function depends on the renin-angiotensin-aldosterone system; consider withholding or discontinuing if progressive renal impairment becomes evident.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• NSAIDs including selective COX-2 inhibitorsIn elderly, volume-depleted or renally compromised patients may cause deterioration of renal function including acute renal failure, and may attenuate the antihypertensive and diuretic effects; monitor renal function.DailyMed (U.S. National Library of Medicine)
• ACE inhibitors, other ARBs, aliskiren (dual RAS blockade)Increased risk of hypotension, hyperkalaemia and changes in renal function; generally avoid; do not co-administer aliskiren in diabetes and avoid it when GFR <60 mL/min.DailyMed (U.S. National Library of Medicine)
• ColesevelamReduces olmesartan exposure; give olmesartan at least 4 hours before colesevelam.DailyMed (U.S. National Library of Medicine)

• Boxed warning: drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus; discontinue as soon as possible when pregnancy is detected and consider alternative antihypertensive therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Amlodipine and hydrochlorothiazide are present in human milk and olmesartan is present in rat milk; because of possible adverse effects on the nursing infant, breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Amlodipine: Inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle; peripheral arterial vasodilator.
• Olmesartan medoxomil: Prodrug hydrolysed to olmesartan, which blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II at the AT1 receptor.
• Hydrochlorothiazide: Promotes renal excretion of sodium and chloride, reducing intravascular volume.